Skip to main content
. Author manuscript; available in PMC: 2011 Nov 7.
Published in final edited form as: Int J Oncol. 2010 Nov;37(5):1297–1305. doi: 10.3892/ijo_00000781

Figure 2.

Figure 2

Y27632 treatment leads to survival and chemoresistance in cisplatin-treated neuroblastoma cells. (A) SK-N-SH (photographed in B), SHEP, and NGP human neuroblastoma cells were treated with 10 μM cisplatin plus the presence (Y) or absence (C) of Y27632 and the number of surviving cells was measured by MTT assay after five days (1st treatment). The surviving cells from the first treatment were then pooled and expanded. These cells were then subjected to a second round of 10 μM cisplatin, and the number of surviving cells was measured by MTT assay after 5 days (2nd treatment). (B) Representative images of SK-N-SM cells 5 days after treatment from (A). (C) Flow cytometric cell cycle analysis of propidium iodide stained SK-N-SH cells collected 48 h following 10 mM cisplatin plus the presence (Cis + Y) or absence (Cis) of Y27632. Locations of the cell cycle phases are diagrammed in the upper panel. The arrow indicates the lack of a sub-G1 population in the Y27632 treated cells.